Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9073 |
High Similarity |
NPD6234 |
Discontinued |
0.894 |
High Similarity |
NPD4966 |
Approved |
0.894 |
High Similarity |
NPD4965 |
Approved |
0.894 |
High Similarity |
NPD4967 |
Phase 2 |
0.879 |
High Similarity |
NPD7228 |
Approved |
0.8742 |
High Similarity |
NPD37 |
Approved |
0.8705 |
High Similarity |
NPD3027 |
Phase 3 |
0.8354 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.8235 |
Intermediate Similarity |
NPD1653 |
Approved |
0.8232 |
Intermediate Similarity |
NPD7240 |
Approved |
0.8176 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.8138 |
Intermediate Similarity |
NPD1613 |
Approved |
0.8138 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8137 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.8 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7988 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7976 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7974 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7917 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7862 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7841 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7821 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7784 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7764 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7725 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7719 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7679 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7667 |
Intermediate Similarity |
NPD7680 |
Approved |
0.766 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7647 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7597 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7588 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7578 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7533 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7533 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7533 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7529 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7517 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7517 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7485 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7485 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7482 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7448 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7442 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.744 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.744 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.744 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7439 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7432 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7423 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7423 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7423 |
Intermediate Similarity |
NPD2977 |
Approved |
0.74 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7397 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7394 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7394 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7389 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7379 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7379 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7378 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7368 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7338 |
Intermediate Similarity |
NPD228 |
Approved |
0.7326 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7325 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7325 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7321 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7317 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7317 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7315 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.731 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7294 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7285 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.7255 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7244 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7244 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7233 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7215 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7212 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7212 |
Intermediate Similarity |
NPD5563 |
Clinical (unspecified phase) |
0.7208 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7194 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7194 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7178 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.7171 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.717 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7162 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7152 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7143 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7143 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7134 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7133 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.711 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7105 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7103 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7101 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7099 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7089 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7083 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7081 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7081 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7078 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7073 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7068 |
Intermediate Similarity |
NPD7827 |
Phase 1 |
0.7059 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7051 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7045 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.7044 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7044 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7039 |
Intermediate Similarity |
NPD6841 |
Approved |
0.7039 |
Intermediate Similarity |
NPD6842 |
Approved |
0.7039 |
Intermediate Similarity |
NPD6843 |
Phase 3 |
0.7037 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7037 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7037 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7037 |
Intermediate Similarity |
NPD2534 |
Approved |
0.703 |
Intermediate Similarity |
NPD7028 |
Phase 2 |
0.7025 |
Intermediate Similarity |
NPD6005 |
Phase 3 |
0.7025 |
Intermediate Similarity |
NPD6002 |
Phase 3 |
0.7025 |
Intermediate Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.7025 |
Intermediate Similarity |
NPD6004 |
Phase 3 |
0.7025 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7025 |
Intermediate Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.7017 |
Intermediate Similarity |
NPD7296 |
Approved |
0.7014 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7013 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7012 |
Intermediate Similarity |
NPD3687 |
Approved |
0.7012 |
Intermediate Similarity |
NPD3686 |
Approved |
0.7007 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7007 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6994 |
Remote Similarity |
NPD1512 |
Approved |
0.6993 |
Remote Similarity |
NPD4625 |
Phase 3 |
0.698 |
Remote Similarity |
NPD1608 |
Approved |
0.6968 |
Remote Similarity |
NPD1558 |
Phase 1 |
0.6964 |
Remote Similarity |
NPD5402 |
Approved |
0.6962 |
Remote Similarity |
NPD2438 |
Suspended |
0.6957 |
Remote Similarity |
NPD2219 |
Phase 1 |
0.6948 |
Remote Similarity |
NPD6798 |
Discontinued |
0.6946 |
Remote Similarity |
NPD6801 |
Discontinued |
0.6943 |
Remote Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.6937 |
Remote Similarity |
NPD3060 |
Approved |
0.6937 |
Remote Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.6928 |
Remote Similarity |
NPD4678 |
Approved |
0.6928 |
Remote Similarity |
NPD4675 |
Approved |
0.6923 |
Remote Similarity |
NPD5735 |
Approved |
0.6923 |
Remote Similarity |
NPD7843 |
Approved |
0.6919 |
Remote Similarity |
NPD7229 |
Phase 3 |
0.6919 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6918 |
Remote Similarity |
NPD3540 |
Phase 1 |
0.6918 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6914 |
Remote Similarity |
NPD7124 |
Phase 2 |
0.6905 |
Remote Similarity |
NPD7819 |
Suspended |
0.6905 |
Remote Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.6899 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6899 |
Remote Similarity |
NPD5588 |
Approved |
0.6894 |
Remote Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.6894 |
Remote Similarity |
NPD3750 |
Approved |
0.689 |
Remote Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.6886 |
Remote Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.6879 |
Remote Similarity |
NPD5242 |
Approved |
0.6879 |
Remote Similarity |
NPD2684 |
Approved |
0.6871 |
Remote Similarity |
NPD6799 |
Approved |
0.6864 |
Remote Similarity |
NPD5353 |
Approved |
0.6859 |
Remote Similarity |
NPD2238 |
Phase 2 |
0.6855 |
Remote Similarity |
NPD3539 |
Phase 1 |
0.6855 |
Remote Similarity |
NPD6100 |
Approved |
0.6855 |
Remote Similarity |
NPD2935 |
Discontinued |
0.6855 |
Remote Similarity |
NPD6099 |
Approved |
0.6852 |
Remote Similarity |
NPD5084 |
Clinical (unspecified phase) |
0.6848 |
Remote Similarity |
NPD5403 |
Approved |
0.6845 |
Remote Similarity |
NPD3384 |
Approved |
0.6845 |
Remote Similarity |
NPD3382 |
Approved |
0.6845 |
Remote Similarity |
NPD3383 |
Approved |
0.6835 |
Remote Similarity |
NPD4538 |
Approved |
0.6835 |
Remote Similarity |
NPD6111 |
Discontinued |
0.6835 |
Remote Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.6835 |
Remote Similarity |
NPD4536 |
Approved |
0.6832 |
Remote Similarity |
NPD5177 |
Phase 3 |
0.6831 |
Remote Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.6826 |
Remote Similarity |
NPD6599 |
Discontinued |
0.6824 |
Remote Similarity |
NPD5585 |
Approved |
0.6821 |
Remote Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.6816 |
Remote Similarity |
NPD8312 |
Approved |
0.6816 |
Remote Similarity |
NPD8313 |
Approved |
0.6815 |
Remote Similarity |
NPD4340 |
Discontinued |
0.6813 |
Remote Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.6807 |
Remote Similarity |
NPD4210 |
Discontinued |
0.6806 |
Remote Similarity |
NPD5535 |
Approved |
0.6795 |
Remote Similarity |
NPD4062 |
Phase 3 |
0.6792 |
Remote Similarity |
NPD4108 |
Discontinued |
0.679 |
Remote Similarity |
NPD6331 |
Phase 2 |
0.679 |
Remote Similarity |
NPD3892 |
Phase 2 |
0.679 |
Remote Similarity |
NPD8166 |
Discontinued |
0.6779 |
Remote Similarity |
NPD17 |
Approved |
0.6779 |
Remote Similarity |
NPD4626 |
Approved |
0.6776
|
Remote Similarity |
NPD1283 |
Approved |